These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 36706655)
21. Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US. Wu L; Zhong L J Med Econ; 2019 Feb; 22(2):187-195. PubMed ID: 30522378 [TBL] [Abstract][Full Text] [Related]
22. Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy. Vulsteke C; Chambers SK; Pérez MJR; Chan JK; Raaschou-Jensen N; Zhuo Y; Lorusso D; Herzog TJ; de la Motte Rouge T; Thomes Pepin JA; Braicu EI; Chen LM; Levy T; Barter JF; Pilar Barretina-Ginesta M; Joosens E; York W; Malinowska IA; González-Martín A; Monk BJ Eur J Cancer; 2024 Sep; 208():114157. PubMed ID: 39013265 [TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Valabrega G; Pothuri B; Oaknin A; Graybill WS; Sánchez AB; McCormick C; Baurain JF; Tinker AV; Denys H; O'Cearbhaill RE; Hietanen S; Moore RG; Knudsen AØ; de La Motte Rouge T; Heitz F; Levy T; York W; Gupta D; Monk BJ; González-Martín A Gynecol Oncol; 2024 Aug; 187():128-138. PubMed ID: 38833992 [TBL] [Abstract][Full Text] [Related]
24. Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial. Belotte J; Felicetti B; Baines AJ; YoussefAgha A; Rojas-Espaillat L; Ortiz AG; Provencher D; Vázquez RM; Cortijo LG; Zeng X Trials; 2024 May; 25(1):301. PubMed ID: 38702828 [TBL] [Abstract][Full Text] [Related]
25. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24. Mirza MR; Bergmann TK; Mau-Sørensen M; Christensen RD; Åvall-Lundqvist E; Birrer MJ; Jørgensen M; Roed H; Malander S; Nielsen F; Lassen U; Brøsen K; Bjørge L; Mäenpää J Cancer Chemother Pharmacol; 2019 Oct; 84(4):791-798. PubMed ID: 31375879 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China. Zhao M; Qiu S; Wu X; Miao P; Jiang Z; Zhu T; Xu X; Zhu Y; Zhang B; Yuan D; Zhang Y; Sun W; He A; Zhao M; Hou W; Zhang Y; Shao Z; Jia M; Li M; Chen J; Xu J; Chen B; Zhou Y; Shen Y Target Oncol; 2023 Nov; 18(6):869-883. PubMed ID: 37847485 [TBL] [Abstract][Full Text] [Related]
27. FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy. Ison G; Howie LJ; Amiri-Kordestani L; Zhang L; Tang S; Sridhara R; Pierre V; Charlab R; Ramamoorthy A; Song P; Li F; Yu J; Manheng W; Palmby TR; Ghosh S; Horne HN; Lee EY; Philip R; Dave K; Chen XH; Kelly SL; Janoria KG; Banerjee A; Eradiri O; Dinin J; Goldberg KB; Pierce WF; Ibrahim A; Kluetz PG; Blumenthal GM; Beaver JA; Pazdur R Clin Cancer Res; 2018 Sep; 24(17):4066-4071. PubMed ID: 29650751 [TBL] [Abstract][Full Text] [Related]
28. What predicts the clinical benefits of PARP inhibitors in platinum-sensitive recurrent ovarian cancer: A real-world single-center retrospective cohort study from China. Zhang D; Li S; Zhang X; Peng J; Zhang S Front Oncol; 2022; 12():955124. PubMed ID: 36059631 [TBL] [Abstract][Full Text] [Related]
29. Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial. Del Campo JM; Matulonis UA; Malander S; Provencher D; Mahner S; Follana P; Waters J; Berek JS; Woie K; Oza AM; Canzler U; Gil-Martin M; Lesoin A; Monk BJ; Lund B; Gilbert L; Wenham RM; Benigno B; Arora S; Hazard SJ; Mirza MR J Clin Oncol; 2019 Nov; 37(32):2968-2973. PubMed ID: 31173551 [TBL] [Abstract][Full Text] [Related]
30. Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trial. Wu X; Zhu J; Yin R; Yang J; Liu J; Wang J; Wu L; Liu Z; Gao Y; Wang D; Lou G; Yang H; Zhou Q; Kong B; Huang Y; Chen L; Li G; An R; Wang K; Zhang Y; Yan X; Lu X; Lu W; Hao M; Wang L; Cui H; Chen Q; Abulizi G; Huang X; Tian X; Wen H; Huang Z; Dong J; Zhang C; Hou J; Mirza MR EClinicalMedicine; 2024 Jun; 72():102629. PubMed ID: 38745967 [TBL] [Abstract][Full Text] [Related]